Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience’s experimental treatment SAT-3247 showed promising results in improving muscle function and regeneration to nearly normal levels in canines with Duchenne muscular dystrophy, without any significant adverse events. The data, indicating the treatment’s potential as a disease-modifying medicine, will be presented at the upcoming World Muscle Society Annual Congress.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
